Merck & Co has announced the US launch of a mobile app designed to help and enhance communications between diabetes patients and educators. US-based Merck said the app known as map4health was ...

It's worth noting that the agreement has been forged a few months after Merck suffered a setback in its attempt to secure FDA approval for a potentially first-in-class drug for chronic cough ...

Are you a print subscriber? Activate your account. By Garett Sloane - 2 hours 35 min ago By Gillian Follett - 2 hours 35 min ago By E.J. Schultz - 2 hours 35 min ago By Jack Neff - 2 hours 35 min ...

Merck's consistent dividend payments over 34 years, healthy balance sheet, and attractive valuation highlight its investment ...

Merck KGaA’sMRK-1.94%decrease; red down pointing triangle shares jumped after the German company said booming artificial-intelligence demand would help its electronics sales grow faster than ...

Merck KGaA said its cell-tumor treatment Pimicotinib met its primary endpoint in a late-stage trial. The German pharma company said Tuesday that its experimental drug showed significant improvement in ...

Oct 17 (Reuters) - German science and technology group Merck (MRCG.DE), opens new tab is open to more acquisitions for its Life Science business after announcing in May it would buy Mirus Bio for ...

Adjusted for one-time items that included a 79-cent-a-share charge related to the business development deals, EPS came to $1.57, ahead of the FactSet consensus of $1.48. Sales rose 4% to $16.657 ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

In this article, we are going to take a look at where Merck & Co., Inc. (NYSE:MRK) stands against other most promising low-cost stocks. The September Consumer Price Index data showed that consumer ...

Merck (MRK) will be in focus as company beats revenue forecasts despite in line earnings amid strong Keytruda sales in Q3 ...